Cargando…
One ring is sufficient to inhibit α-synuclein aggregation
Parkinson’s disease, the second most prevalent neurodegenerative disorder worldwide, is characterized by a progressive loss of dopaminergic neurons in substantia nigra pars compacta, causing motor symptoms. This disorder’s main hallmark is the formation of intraneuronal protein inclusions, named Lew...
Autores principales: | Peña-Díaz, Samuel, Ventura, Salvador |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504378/ https://www.ncbi.nlm.nih.gov/pubmed/34380879 http://dx.doi.org/10.4103/1673-5374.320973 |
Ejemplares similares
-
Small molecules to prevent the neurodegeneration caused by α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2020) -
Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease
por: Peña-Díaz, Samuel, et al.
Publicado: (2023) -
Inducing α-synuclein compaction: a new strategy for inhibiting α-synuclein aggregation?
por: Pinheiro, Francisca, et al.
Publicado: (2019) -
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease
por: Vittorio, Serena, et al.
Publicado: (2020) -
Inhibition of α-Synuclein Aggregation and Mature Fibril Disassembling With a Minimalistic Compound, ZPDm
por: Peña-Díaz, Samuel, et al.
Publicado: (2020)